SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (4591)6/29/1998 12:28:00 PM
From: Steve Fancy  Respond to of 6136
 
Izzy, AGPH will go up before November option expiration. I've got a lot riding on that date.

sf



To: Izzy who wrote (4591)6/29/1998 12:38:00 PM
From: sam  Read Replies (1) | Respond to of 6136
 
This may be a dumb question, but does anyone know the differences between Sustiva and S-1153? Seems to me they are aiming at the same result. When will Sustiva come to market? This is not a request for others to do my work for me. FWIW, I'll be looking into this, too. The more I learn about AIDS meds (or any med for that matter), the less I seem to know.



To: Izzy who wrote (4591)6/29/1998 12:46:00 PM
From: scaram(o)uche  Respond to of 6136
 
Izzy:

These are, IMO, CYA steps. These are leveraging modest up-front moneys to put a potential bulge in the mid-term pipe. I smell a "Chiron like" deal coming. I thought that they would take the money and run, but Johnson is instead electing to just torture Glaxo, DuPont and others with a "what if" scenario. Johnson is not making the "Binder Error".

Rick


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News